Increased eosinophil counts have been recognised to be linked to asthma severity and are a risk factor for asthma exacerbations. Therefore, decreasing eosinophil count by targeting the interleukin-5-mediated signalling pathway could help to reduce airway inflammation and improve asthma treatment control. In The Lancet Respiratory Medicine, Mario Castro and colleagues1 report data from two large, randomised, placebo-controlled trials, in which reslizumab, a neutralising monoclonal antibody for interleukin 5, was safe and effective in patients with severe eosinophilic asthma.
Recent Posts
- A Meta-Analysis Investigating the Efficacy and Safety of Allergen-Specific Immunotherapy in the Management of Respiratory Allergies
- A Quarter of Patients With Mild Asthma Don’t Receive Guideline-Directed Therapy
- Computer fraud
- Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
- Asthma – how new medicines and services are improving lives?